Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
11.34
+0.35 (3.18%)
Mar 25, 2026, 4:00 PM EDT - Market closed
Keros Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts that cover Keros Therapeutics stock have a consensus rating of "Buy" and an average price target of $22.25, which forecasts a 96.21% increase in the stock price over the next year. The lowest target is $16 and the highest is $27.
Price Target: $22.25 (+96.21%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Keros Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 5 | 5 | 5 | 5 | 3 |
| Hold | 8 | 7 | 7 | 7 | 7 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 15 | 15 | 15 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $23 → $20 | Buy | Maintains | $23 → $20 | +76.37% | Mar 5, 2026 |
| B of A Securities | B of A Securities | Hold Maintains $18 → $19 | Hold | Maintains | $18 → $19 | +67.55% | Nov 28, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $23 → $27 | Buy | Reiterates | $23 → $27 | +138.10% | Nov 12, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $26 → $23 | Buy | Maintains | $26 → $23 | +102.82% | Nov 11, 2025 |
| Wedbush | Wedbush | Hold Maintains $15 → $16 | Hold | Maintains | $15 → $16 | +41.09% | Nov 6, 2025 |
Financial Forecast
Revenue This Year
340.00K
from 244.06M
Decreased by -99.86%
Revenue Next Year
2.81M
from 340.00K
Increased by 727.07%
EPS This Year
-3.62
from 2.30
EPS Next Year
-4.02
from -3.62
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2.1M | 15.8M | |||
| Avg | 339,997 | 2.8M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -99.1% | 4,532.4% | |||
| Avg | -99.9% | 727.1% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.34 | -2.86 | |||
| Avg | -3.62 | -4.02 | |||
| Low | -4.82 | -5.60 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.